Infection, Human Immunodeficiency Virus I Clinical Trial
Official title:
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ZIAGEN® Administered in Korean Patients According to the Prescribing Information
An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ZIAGEN® administered in Korean patients according to the prescribing information.
This study will collect clinical data, mainly focused on safety, in Korean population as per
the requirement of KFDA for market authorization.
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
updating systems to reflect the change in sponsorship.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03327740 -
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
|
||
| Completed |
NCT00257621 -
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
|
Phase 2 | |
| Completed |
NCT01227824 -
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
|
Phase 3 | |
| Completed |
NCT01597648 -
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
|
Phase 1 | |
| Withdrawn |
NCT01283100 -
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
|
Phase 1 | |
| Completed |
NCT00450580 -
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
|
Phase 3 | |
| Completed |
NCT00440947 -
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
|
Phase 3 | |
| Completed |
NCT00549198 -
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
|
Phase 4 | |
| Completed |
NCT00481390 -
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients
|
N/A | |
| Completed |
NCT00242840 -
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
|
Phase 3 | |
| Terminated |
NCT00197145 -
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
|
Phase 3 | |
| Completed |
NCT00089583 -
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
|
Phase 2 | |
| Completed |
NCT00044577 -
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
|
Phase 3 | |
| Terminated |
NCT00104429 -
GW873140 In Combination With Combivir In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT01263015 -
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
|
Phase 3 | |
| Terminated |
NCT00102778 -
GW873140 In Combination With Kaletra In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT00094523 -
Fosamprenavir Versus Other Protease Inhibitors
|
Phase 3 | |
| Completed |
NCT00046176 -
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
|
Phase 3 | |
| Terminated |
NCT00242879 -
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
|
Phase 2 | |
| Completed |
NCT00082394 -
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
|
Phase 4 |